MEI Pharma Shifts Gears: Launching $100M Litecoin Treasury and Appointing Charlie Lee to the Board

MEI Pharma, a U.S.-based biotechnology firm, has made headlines by announcing the launch of a $100 million Litecoin (LTC) Treasury Strategy, becoming the first publicly traded company to adopt Litecoin as its primary reserve asset. This groundbreaking shift blends traditional biotech with the forward momentum of digital finance.

$100 Million PIPE Deal

The company entered into a definitive agreement to raise approximately $100 million through a Private Investment in Public Equity (PIPE) deal. The offering includes roughly 29.24 million common shares (or pre-funded warrants) at a price of $3.42 per share. All net proceeds will be used exclusively to purchase Litecoin, establishing a long-term crypto-backed financial reserve.

Charlie Lee Joins the Board

In a strategic and symbolic move, Charlie Lee, the creator of Litecoin, will join MEI Pharma’s Board of Directors following the closing of the financing. He replaces outgoing board member Taheer Datoo.

Lee expressed enthusiasm about the decision, noting that Litecoin’s core principles—speed, security, and decentralization—align well with corporate treasury needs in the modern economy. His presence is expected to boost both investor confidence and internal strategic direction.

Strategic Oversight by GSR

The company’s Litecoin treasury operations will be managed by GSR, a leading digital asset manager and market-maker. GSR will provide guidance on treasury implementation, asset custody, and regulatory compliance, ensuring a professional and secure process.

Institutional Support

MEI’s bold direction is supported by several notable institutional investors, including the Litecoin Foundation, MOZAYYX, ParaFi, Hivemind, CoinFund, Delta Blockchain, Primitive, and RLH Capital. Their participation reinforces the legitimacy and potential of integrating cryptocurrency into public company treasuries.

Market Impact

Following the announcement, MEI Pharma’s stock surged by over 100%, reflecting investor optimism and strong market demand for innovation at the intersection of biotech and crypto. This move sets a new precedent that may encourage other companies to explore similar strategies.

What's Next?

  • The financing is expected to close on or about July 22, 2025, subject to customary closing conditions.

  • Following the close, MEI Pharma will file a resale registration statement with the SEC for the newly issued shares.

  • The company is expected to begin acquiring Litecoin shortly thereafter.

Popular posts from this blog

Silver’s Brutal 2026 Crash: Why Prices Collapsed From Over $120 to the High-$60s

Image
Silver’s Collapse From Over $120 to the High-$60s: What Triggered the Most Violent Shakeout in Decades? March 2026 has become a month silver investors will not forget. After soaring to extraordinary highs earlier this year, silver has gone through a brutal reversal. Prices that traded above $120 at the peak of the rally are now sitting near the high-$60s, wiping out a massive portion of value in just a matter of weeks. Front-month silver futures recently traded around $67–$69, far below their January extremes. This was not a normal pullback. It was a full-scale market washout — fast, aggressive, and unforgiving. For leveraged traders, the drop has already been devastating. For long-term investors, however, the bigger question is only beginning: Is this the start of a deeper downtrend, or the kind of panic-driven collapse that creates the next major buying opportunity? What Happened to Silver in 2026? Silver had been one of the hottest assets in the market. The metal surged sha...
Read more

Sector Rotation 2026: Money Isn’t “Fleeing Tech”—It’s Rotating Selectively (With Stock & ETF Ideas)

Image
Sector Rotation 2026: Money Isn’t “Running From Tech”—It’s Rotating, Selectively Early 2026 feels confusing for many investors. Good headlines seem to arrive daily, yet the market looks like it’s going nowhere. Here’s the truth: the index can be flat while money is moving aggressively underneath. What we’re seeing is classic Sector Rotation —capital flowing out of areas that already ran far, into sectors that are cheaper , more cyclical , and better positioned if the economy keeps progressing . The core mindset shift in this rotation is: From “buying the basket” → to “picking winners” From “storytelling” → back to “profits, cash flow, and pricing power” 1) How This Rotation Is Happening in 2026 After multiple years of strong performance in AI/Big Tech , many investors are simply locking in profits and reallocating toward cyclical/value sectors—areas that often perform well when: growth stabilizes (instead of accelerating), rates stop rising (or begin to ease), earni...
Read more

Trip.com Q2 2026: Earnings and the China Hotel Moat

Image
TRIP.COM GROUP / Q2 2026 EARNINGS ANALYSIS Growth holds. The moat faces a new test. Hotel economics, international growth and the questions beyond the antitrust charge. Explore the analysis 13 MIN READ / SEPTEMBER 2026 NET REVENUE RMB15.7bn +6% year over year ADJUSTED EBITDA MARGIN 29% 33% a year earlier INTERNATIONAL REVENUE >50% Year-over-year growth Snapshot: Trip.com Q2 2026 results Updated September 17, 2026. Analysis of unaudited results for the quarter ended June 30, 2026. Trip.com Q2 2026 earnings tell two different stories. Revenue continued to grow, while a substantial antitrust charge pushed the company into a reported net loss. The longer-term question is whether changes to its hotel partnerships will reduce the profitability of its domestic China business. The roughly RMB5.18 billion charge is significant. But an accounting adjustment cannot answer the question that matters most for future earnings: how much bargaining power will Trip.com reta...
Read more

IREN Stock Drops After Earnings Even as AI Cloud Growth Accelerates—What Is the Market Worried About?

Image
IREN’s AI demand story is getting stronger, but investors now want proof that $4 billion of contracted ARR can become revenue and cash flow before capital spending, financing costs and dilution catch up. IREN shares closed Thursday’s regular session at $40.53, up 2.4%, before falling to approximately $37.11 in extended trading—a decline of more than 8%—following the release of its fiscal 2026 results. At first glance, the reaction suggested that investors were disappointed with the earnings report. But the underlying story is more complicated. IREN’s AI Cloud business is still expanding rapidly. The company has secured approximately $4 billion of contracted annualized run-rate revenue, or ARR, for capacity scheduled to become operational during calendar 2026. Its 2026 capacity is largely sold out, and the company has added another unnamed frontier AI laboratory to a customer list that already includes Cohere, Prometheus, Perplexity, Figure AI, Fal AI and Higgsfield AI. The question fac...
Read more

U.S. Stock Market Loses $400B After Iran Red Sea Threat

Image
U.S. Stock Market Reportedly Loses Over $400 Billion After Iran Threatens Bab el-Mandeb Strait Rising Middle East Tensions Shake Wall Street The U.S. stock market came under fresh pressure after Iran reportedly warned that the Bab el-Mandeb Strait, a key gateway into the Red Sea, could be targeted or closed if the United States attacks Iran’s energy infrastructure. The threat immediately raised concerns across global financial markets. Investors reacted by reducing exposure to risk assets, with U.S. equities reportedly losing more than $400 billion in market value as fears grew over a wider conflict, higher oil prices, and potential disruption to global shipping. According to Reuters, Iran has told Yemen’s Houthi movement to prepare for action around the Bab el-Mandeb route if U.S. strikes hit Iranian power infrastructure. The report added that the strategic waterway is important for global energy flows and could become another pressure point in the broader U.S.-Iran confrontation. Why...
Read more